Acute  myeloid  leukemia  (AML) is  the  most common leukemia among  the  adult  population  and  accounts  for  about  80%  of  all cases, and its characterized  by clonal expansion of  immature “blast cells” in the peripheral  blood and  bone marrow .The stem cell marker CD34 is expressed by leukemia blasts only for a subset of patients with acute myelogenous leukemia (AML).The aim of this study is to determine the role of CD34 in AML and its relationship with the parameters of complete blood (CBC). A total of (60) venous blood sample from patients and (30) control their ages ranged between 18 and 66 years, The samples was collected from Baghdad medical city hospital. Sera from all participants were tested to assessment CD34 level by ELISA.In the current study, CD34 in patients and control groups show a significant difference in relation with AML patients   at p-value (< 0.001). The levels of CD34 in the patients were 0.55 ± 0.03, whereas it’s significantly increased to 0.81 ± 0.05 in the control. also we found The majority of patients presented with subtype M3 38.3% of total patients.

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cells which are characterized by relevant heterogeneity in terms of phenotypic, genotypic, and clinical features. Among the genetic aberrations that control disease development there are microRNAs (miRNAs). The  present study aimed to investigate  the role of miRNAs in diagnosis and prognosis of AML and it was designed as cross sectional study in patients with acute myeloid leukemia and normal individuals as control group, we determined: RNA yield and quality; and quantification of miRNA-203, miRNA-143, and miRNA-495 expression by Quantitative Real-Time PCR (qPCR) in the serum of AML patients and control groups. The study was conducted in  period between December 2020 and September 2021 at the University of Babylon, College of Science, department of biology. In this case-control study, blood samples were collected from 115 AML patients (38 male and 77 female) and their ages ranged between 18 and 66 years ,  then, 60 patients were selected based on the quantity and natural color of their samples (28 male and 32 female), in addition to the 30 samples from healthy apparently subjects as a control group (11 male and 19 female), and this group matched with the patients groups.

Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases, and its characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow. The stem cell marker CD34 is expressed by leukemia blasts only for a subset of patients with acute myelogenous leukemia (AML). The aim of this study is to determine the role of CD34 in AML and its relationship with the parameters of complete blood (CBC). A total of (60) venous blood sample from patients and (30) control their ages ranged between 18 and 66 years, the samples was collected from Baghdad medical city hospital. Sera from all participants were tested to assessment CD34 level by ELISA. In the current study, CD34 in patients and control groups show a significant difference in relation with AML patients at p-value (<0.001). The levels of CD34 in the patients were 0.55 ± 0.03, whereas it's significantly increased to 0.81 ± 0.05 in the control. Also we found the majority of patients presented with subtype M3 38.3% of total patients.

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cells which are characterized by relevant heterogeneity in terms of phenotypic, genotypic, and clinical features. Among the genetic aberrations that control disease development there are microRNAs (miRNAs). The  present study aimed to investigate  the role of miRNAs in diagnosis and prognosis of AML and it was designed as cross sectional study in patients with acute myeloid leukemia and normal individuals as control group, we determined: RNA yield and quality; and quantification of miRNA-203, miRNA-143, and miRNA-495 expression by Quantitative Real-Time PCR (qPCR) in the serum of AML patients and control groups. The study was conducted in  period between December 2020 and September 2021 at the University of Babylon, College of Science, department of biology. In this case-control study, blood samples were collected from 115 AML patients (38 male and 77 female) and their ages ranged between 18 and 66 years ,  then, 60 patients were selected based on the quantity and natural color of their samples (28 male and 32 female), in addition to the 30 samples from healthy apparently subjects as a control group (11 male and 19 female), and this group matched with the patients groups.